EP1276753A4 - Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease - Google Patents

Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease

Info

Publication number
EP1276753A4
EP1276753A4 EP01925837A EP01925837A EP1276753A4 EP 1276753 A4 EP1276753 A4 EP 1276753A4 EP 01925837 A EP01925837 A EP 01925837A EP 01925837 A EP01925837 A EP 01925837A EP 1276753 A4 EP1276753 A4 EP 1276753A4
Authority
EP
European Patent Office
Prior art keywords
developing
risk
determining
cardiovascular disease
hyperglycemic patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01925837A
Other languages
German (de)
French (fr)
Other versions
EP1276753A2 (en
EP1276753B1 (en
Inventor
Andrew P Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/556,469 external-priority patent/US6251608B1/en
Priority claimed from US09/688,121 external-priority patent/US6599702B1/en
Priority claimed from US09/815,016 external-priority patent/US6613519B1/en
Application filed by Rappaport Family Institute for Research in the Medical Sciences filed Critical Rappaport Family Institute for Research in the Medical Sciences
Publication of EP1276753A2 publication Critical patent/EP1276753A2/en
Publication of EP1276753A4 publication Critical patent/EP1276753A4/en
Application granted granted Critical
Publication of EP1276753B1 publication Critical patent/EP1276753B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
EP01925837A 2000-04-20 2001-04-19 Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease Expired - Lifetime EP1276753B1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US815016 1997-03-14
US09/556,469 US6251608B1 (en) 2000-04-20 2000-04-20 Method of determining a potential of a hyperglycemic patients of developing vascular complications
US556469 2000-04-20
US23769600P 2000-10-05 2000-10-05
US237696P 2000-10-05
US09/688,121 US6599702B1 (en) 2000-04-20 2000-10-16 Method of evaluating a risk of a subject of developing vascular complications
US688121 2000-10-16
US27353801P 2001-03-07 2001-03-07
US273538P 2001-03-07
US09/815,016 US6613519B1 (en) 2000-04-20 2001-03-23 Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
PCT/IL2001/000369 WO2001080712A2 (en) 2000-04-20 2001-04-19 Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease

Publications (3)

Publication Number Publication Date
EP1276753A2 EP1276753A2 (en) 2003-01-22
EP1276753A4 true EP1276753A4 (en) 2007-04-25
EP1276753B1 EP1276753B1 (en) 2010-01-06

Family

ID=27540087

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01925837A Expired - Lifetime EP1276753B1 (en) 2000-04-20 2001-04-19 Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease

Country Status (6)

Country Link
EP (1) EP1276753B1 (en)
AU (1) AU5251201A (en)
DK (1) DK1276753T3 (en)
ES (1) ES2341221T3 (en)
PT (1) PT1276753E (en)
WO (1) WO2001080712A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608393B2 (en) 2000-04-20 2009-10-27 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2016046636A2 (en) * 2014-09-05 2016-03-31 American University Of Beirut Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037419A1 (en) * 1997-02-19 1998-08-27 Dade Behring Marburg Gmbh Method and kit for determining the phenotype of a haptoglobin and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037419A1 (en) * 1997-02-19 1998-08-27 Dade Behring Marburg Gmbh Method and kit for determining the phenotype of a haptoglobin and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DELANGHE J ET AL: "Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery.", ATHEROSCLEROSIS 25 JUL 1997, vol. 132, no. 2, 25 July 1997 (1997-07-25), pages 215 - 219, XP002421565, ISSN: 0021-9150 *
LANGLOIS M R ET AL: "Biological and clinical significance of haptoglobin polymorphism in humans.", CLINICAL CHEMISTRY OCT 1996, vol. 42, no. 10, October 1996 (1996-10-01), pages 1589 - 1600, XP002421564, ISSN: 0009-9147 *
LEVY A P ET AL: "Haptoglobin phenotype and vascular complications in patients with diabetes.", THE NEW ENGLAND JOURNAL OF MEDICINE 28 SEP 2000, vol. 343, no. 13, 28 September 2000 (2000-09-28), pages 969 - 970, XP009079334, ISSN: 0028-4793 *
PRABHA P S ET AL: "HAPTOGLOBIN PATTERNS IN ESSENTIAL HYPERTENSION AND ASSOCIATED CONDITIONS - INCREASED RISK FOR HP 2-2", HUMAN HEREDITY, KARGER, BASEL, CH, vol. 37, 1987, pages 345 - 348, XP002949217, ISSN: 0001-5652 *
ROGUIN A ET AL: "Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty.", THE AMERICAN JOURNAL OF CARDIOLOGY 1 FEB 2001, vol. 87, no. 3, 1 February 2001 (2001-02-01), pages 330 - 332 , A9, XP002421563, ISSN: 0002-9149 *
See also references of WO0180712A3 *

Also Published As

Publication number Publication date
WO2001080712A3 (en) 2002-03-14
AU5251201A (en) 2001-11-07
ES2341221T3 (en) 2010-06-17
EP1276753A2 (en) 2003-01-22
PT1276753E (en) 2010-04-14
DK1276753T3 (en) 2010-05-17
WO2001080712A2 (en) 2001-11-01
EP1276753B1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
EP1372471A4 (en) A multi-tier method of developing localized calibration models for non-invasive blood analyte prediction
AU2001247794A1 (en) Computerized interactive method and system for determining risk of developing a disease and the consequences of developing the disease
IL137045A0 (en) A non-invasive method and apparatus for measuring the mechanical performance of the heart
IL174127A0 (en) Apparatus for, and method of, determining the condition of a patient's heart
AU1678800A (en) A method of optical measurements for determining various parameters of the patient's blood
HK1035505A1 (en) Method of confirming performer of exercise.
AU2001275047A1 (en) Method of graphically indicating patient information
FI20010019A0 (en) A method for diagnosing atrophic disease
ZA200300418B (en) Method of treating cardiovascular disease.
IL205264A0 (en) Transmittal of heartbeat signal at a lower level than heartbeat request
WO2002006840A3 (en) A rapid non-invasive method for differential acute cardiovascular disease diagnosis
HK1066861A1 (en) Method of measuring whole blood
EP1276753A4 (en) Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
GB2370487B (en) Method and apparatus for obtaining neutral foot position and correction of pathological foot movements
IL145714A0 (en) Prediction of risk of interstitial lung disease
IL162229A0 (en) Method for obtaining oestrogen frommare urine
AU2002366126A1 (en) Method for evaluation of the risk of cardiovascular disease
FI20021783A (en) A method for detecting the risk of cardiovascular disease
HK1044294B (en) Method of surface modifying a medical tubing
EP1438431A4 (en) Methods for diagnosing and treating heart disease
GB0023599D0 (en) Non-invasive method for determining human photodermatoogical skin-types
EP1408808A4 (en) Methods for diagnosing and treating heart disease
AU2002350765A1 (en) Method for assessing the risk of cardiovascular disease
GB0024938D0 (en) Method of diagnosis
AU2003221918A1 (en) A method for identifying at risk cardiovascular disease patients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20021019;LT PAYMENT 20021019;LV PAYMENT 20021019;MK PAYMENT 20021019;RO PAYMENT 20021019;SI PAYMENT 20021019

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEVY, ANDREW, P.

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20070315BHEP

Ipc: C07H 21/04 20060101AFI20020422BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070323

17Q First examination report despatched

Effective date: 20071123

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60141006

Country of ref document: DE

Date of ref document: 20100225

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100406

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100400832

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2341221

Country of ref document: ES

Kind code of ref document: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100106

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20100422

Year of fee payment: 10

Ref country code: PT

Payment date: 20100415

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100422

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100106

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20100416

Year of fee payment: 10

26N No opposition filed

Effective date: 20101007

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100429

Year of fee payment: 10

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111019

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20111024

Year of fee payment: 11

Ref country code: FI

Payment date: 20111027

Year of fee payment: 11

Ref country code: SE

Payment date: 20111012

Year of fee payment: 11

Ref country code: NL

Payment date: 20111020

Year of fee payment: 11

Ref country code: BE

Payment date: 20111013

Year of fee payment: 11

Ref country code: IE

Payment date: 20111020

Year of fee payment: 11

Ref country code: DK

Payment date: 20111012

Year of fee payment: 11

Ref country code: CH

Payment date: 20111012

Year of fee payment: 11

BERE Be: lapsed

Owner name: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE ME

Effective date: 20120430

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20121101

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 454391

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120419

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20100400832

Country of ref document: GR

Effective date: 20121102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120419

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120419

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121102

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120419

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20190226

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200420

Year of fee payment: 20

Ref country code: FR

Payment date: 20200420

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200427

Year of fee payment: 20

Ref country code: IT

Payment date: 20200428

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60141006

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20210418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20210418

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200420